Introduction. Biopsy of affected tissue is required for lymphoma diagnosis at onset and relapse and to plan an adequate treatment. Open incisional biopsy is traditionally the method of choice, with an accuracy of approximately 100%. Nevertheless, it requires hospitalization, availability of an operating room and sometimes general anesthesia and is associated with several drawbacks (morbidity, surgical complications, tumor contamination of surrounding tissues). The development of ultrasound and computed tomography (CT)-guided fine-needle biopsies has almost overcome these disadvantages. However, a variable proportion of non-diagnostic procedures is reported, leading to an accuracy that ranges between 50% and 80%. Functional imaging, such as fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT is a procedure which can potentially be used to drive biopsy to the most metabolically active area within a lymph node or to extranodal masses which sometimes show no morphologically detectable changes on CT scan.